anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a drug delivery system consisting of a thermoplastic core polymer incorporated with plural active substances and a thermoplastic skin layer permeable to the active substances, and capable of constantly releasing the plural active substances for a long time by dissolving the active substances in the polymer core, to the extent of low supersaturation degree in the initial stage of assembling of the system. SOLUTION: This system comprises a thermoplastic polymer core l (e.g. poly-EVA) incorporated with a progesterone-based compound (e.g. etonogestrel) and an estrogenic-based compound (e.g. ethynylestradiol) (the progesterone-based compound is dissolved at 1-about 6 weight times that necessary for making its saturated concentration, while the estrogenic-based compound is dissolved to make a lower concentration.), and a thermoplastic skin layer 2 coating the core 1, and permeable to both of the above compounds and capable of adjusting the released concentrations of the respective compounds. This system is used especially as a contraceptive ring.
Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
A composition for suppressing deterioration of an acquired immune function according to the present invention includes, as an active ingredient, lactic acid bacteria products from lactic acid bacteria of the genus Lactobacillus. This composition for suppressing deterioration of the acquired immune function suppresses deterioration of the acquired immune function due to the use of an anti-influenza drug. The lactic acid bacteria of the genus Lactobacillus is preferably a bulgaricus bacterium. For example, the lactic acid bacteria of the genus Lactobacillus may be Lactobacillus delbrueckii subsp. bulgaricus. In the production method according to the present invention, a milk raw material is supplied to lactic acid bacteria of the genus Lactobacillus in order to produce the composition for suppressing deterioration of the acquired immune function to suppress deterioration of the acquired immune function due to the use of an anti-influenza drug.
FIELD: medicine, oncology, chemical- -pharmaceutical industry. SUBSTANCE: invention relates to development of antitumor agent containing ampicillin sodium salt, medicinal bile, iodine alcoholic solution, sugar and water for injections taken at the definite ratio. Checking shows high antitumor activity of agent in experimental animals with transplantable tumors and cytotoxic activity in cultured cells, effectiveness in treatment of cows with leukosis and positive results of treatment of five patients with malignant tumors. Agent shows effectiveness in treatment of both solid and ascite forms of malignant tumors, metastatic forms, decrease of metastasizing and in treatment of diseases with hemopoiesis disturbances. EFFECT: enhanced antitumor activity of agent. 1 cl, 4 tbl, 9 ex
In healthy subjects, low-grade inflammation, as measured by serum levels of cytokines or acute phase proteins, is positively associated with adiposity. Recent studies indicate that chronic low-grade inflammation in non-diabetic individuals may cause decline in insulin sensitivity and increases the risk of developing type 2 diabetes. It has been proposed that reduction of low-grade inflammation may reduce the risk of development of type 2 diabetes. In agreement with this hypothesis, the class of anti-inflammatory drugs called salicylates (such as aspirin) that influence a specific anti-inflammatory pathway have been found to decrease plasma glucose levels and increase insulin sensitivity in rodents as well as people with type 2 diabetes.

In the present study, we propose testing whether administration of the anti-inflammatory drug Salsalate improves insulin sensitivity in obese non-diabetic individuals and whether this improvement is related with a decrease in serum markers of inflammation. Subjects will be randomly assigned to two treatment groups: placebo or Salsalate (3g/d). An oral glucose tolerance test and a combined euglycemic/hyperglycemic clamp to assess insulin sensitivity and insulin secretion will be performed before and after seven days of treatment. Results of this study may help to identify novel strategies to prevent type 2 diabetes in high-risk groups.
<P>PROBLEM TO BE SOLVED: To provide a fermentation-treated material of Hemerocallis fulva var. sempervirens exhibiting better sleep improving actions or an ACE (angiotensin I converting enzyme) inhibitory activity than those of ingestion of the plant of the Hemerocallis fulva var. sempervirens itself and a food material and a food containing the fermented plant in order to effectively utilize the Hemerocallis fulva var. sempervirens.  <P>SOLUTION: The fermentation-treated material exhibits sleep improving effects as compared with those of the plant Hemerocallis fulva var. sempervirens by a fermentation treatment of the Hemerocallis fulva var. sempervirens and improves taste. The lactic acid fermentation-treated material exhibiting the ACE inhibitory activity effects can be obtained. Furthermore, the food material and food having great utilization value with enhanced actions can be obtained.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE: This study aimed to determine whether the combination of H2 gas inhalation and administration of hydrogen-rich acetated Ringer's solution (HS) could protect against ischemic spinal cord injury in rabbits.
METHODS: In Experiment 1, rabbits were randomly assigned to a 1.2% H2 gas group, HS group, 1.2% H2 gas + HS group (combination group), or control group (n = 6 per group). The H2 concentration of HS was 0.65 mM. H2 was inhaled for 60 min, starting 5 min before reperfusion. HS (20 mL/kg) was divided into six bolus injections at 10-min intervals, starting 5 min before reperfusion. Spinal cord ischemia was produced by occluding the abdominal aorta for 15 min. Neurologic and histopathologic evaluations were performed 7 days after reperfusion. In Experiment 2, H2 concentrations in spinal cord tissue according to the administration of 1.2% H2 gas or HS were compared by measuring the electric current through a platinum needle electrode (n = 2). In Experiment 3, rabbits were assigned to a 2% H2 gas group or control group (n = 6 per group). Spinal cord ischemia was produced and neurologic and histopathologic evaluations were performed as in Experiment 1.
RESULTS: There were no significant differences among the groups in the neurologic and histopathologic outcomes in Experiments 1 and 3. Bolus administration of HS (10 mL) transiently increased the current to only 1/30th and 1/27th of the plateau current with 1.2% H2 gas inhalation in two animals.
CONCLUSION: These results suggest that the combination of 1.2% H2 gas inhalation and administration of a hydrogen-rich solution does not protect against ischemic spinal cord injury and that the increase in H2 concentration in spinal cord tissue after administration of HS is very low compared to 1.2% H2 gas inhalation.
Risk Summary

There are no data on the presence of ranolazine in human milk, the effects on the breastfed infant, or the effects on milk production. However, ranolazine is present in rat milk [see Use in Specific Populations (8.1)] . The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Ranolazine extended-release tablets and any potential adverse effects on the breastfed infant from Ranolazine extended-release tablets or from the underlying maternal condition. 

Adult female rats were administered ranolazine orally from gestation day 6 through postnatal day 20. No adverse effects on pup development, behavior, or reproduction parameters were observed at a maternal dosage level of 60 mg/kg/day (equal to the MHRD based on AUC). At maternally toxic doses, male and female pups exhibited increased mortality and decreased body weight, and female pups showed increased motor activity. The pups were potentially exposed to low amounts of ranolazine via the maternal milk.
All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
Gels contg. a vegetable oil and aluminium monostearate (I), suitable for use as suspending media for pharmaceutical products, are prepd. by heating the oil and (I) to 132-136 degrees C, then cooling rapidly to 20 degrees C. The gels are more stable and viscous than gels prepd. conventionally. In an example gels were made from a nut oil and 2% (I). One was made conventionally and the other was made as described above. Their viscosities at 18 degrees C were 20.62 and 53.92 Engler respectively.
Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with TOPAMAX ® use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures. 

The majority of the reports have been in pediatric patients. Patients (especially pediatric patients) treated with TOPAMAX ® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when TOPAMAX ® is given with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.
Radiotherapy plays an integral role in breast cancer therapy. Multiple randomized studies have demonstrated decreased local-regional recurrence rates and decreased breast-cancer mortality. However, balanced with this survival benefit is the potential toxicity of the treatment itself. In particular, cardiac effects of radiotherapy have been a concern and an area of research for the past 20 years. From long-term follow up of patients with lymphoma, it is known that radiotherapy can lead to increased risk of myocardial infarction, valvular dysfunction, systolic and diastolic function abnormalities, and heart failure among cancer-survivors. Patients with breast cancer receive lower doses to smaller volumes of the heart, but they also have an excellent long-term survival, so it is crucial to study the effects of low dose radiotherapy. Indeed, a recent study suggests that these effects can be seen within the first 5 years after treatment, and that there is no dose threshold. The investigators hypothesize that they can develop imaging and blood biomarkers of cardiac exposure, as a first step to identifying patients at increased risk for cardiac effects. These patients can then be targeted for close monitoring and early intervention, potentially with statins or ACE inhibitors. Additionally, by characterizing a time-course and radiation dose-volume relationship, potentially real-time modifications can be made to RT field design for patients sensitive to RT effects. Finally, this information can be incorporated into better designs of treatment plans for future patients.
The invention relates to a method for producing high purity for radiopharmaceutical purposes 68 A method of Ge material. The invention relates in particular to compliance with Good Manufacturing Practice (GMP) 68 Production of Ge-API (API ═ active pharmaceutical ingredient) solutions. The starting materials for the process of the invention may be of commercial or other origin 68 Ge stock solution was used as raw material. Such as a container comprising 68 The raw Ge solution is purified from potential metallic and organic impurities originating from the production process. The disclosed radiochemical method is based on the dual separation of Ge from organic and metallic impurities with two different adsorption materials. Purification from organic and metallic impurities by adsorption in the form of germanium tetrachloride during the first separation stage 68 Ge, followed by purification of the hydrolyzed from remaining metal impurities by cation exchange 68 And Ge. Final product of 68 Ge-API products, e.g. in accordance with 68 Ge/ 68 The regulatory requirements of GMP production specifications for Ga generators.
The present disclosure relates to a new lymphokine molecule, referred to as Monocyte Cytotoxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isolation and purification. Sezary's Syndrome is a leukemic proliferation of OKT4+ lymphocytes. Sezary cells were isolated by differential centrifugation and fused to CEM.8aza. r C, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cytotoxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized. Monocyte cytotoxicity inducing factor was found to be stable at pH 2 for one hour, unlike interferon-gamma, and was found to be more heat stable as well. Moreover, treatment of MCF with antisera to interferons gamma, alpha, or a combination of gamma and alpha failed to neutralize its biologic activity. MCF binds to Matrex Gel Red A. MCF eluted from this dye-ligand was found to have an apparent molecular weight of 11,500 Daltons by gel filtration and 14,700 Daltons by SDS-polyacrylamide gel electrophoresis. (SDS-PAGE). A molecular weight of 29,000 daltons was found by use of SDS-PAGE in a second species of MCF produced under serum-free conditions.
INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) together with iron supplementation had been the standard treatment for anemia in chronic kidney disease (CKD) for the past decades. Recently, hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have attracted attention as a novel treatment option.
AREAS COVERED: This review summarizes the effectiveness and the safety of HIF-PHIs based on previous clinical trials and discusses points to consider for their clinical use.
EXPERT OPINION: The results from clinical trials demonstrate that HIF-PHIs are non-inferior to ESAs in terms of the efficacy to maintain or improve blood hemoglobin levels. However, concerns about adverse events including cardiovascular outcomes, thrombotic events, and tumor progression have prevented HIF-PHIs from being widely approved for clinical use. Also, long-term safety has not been demonstrated yet. Practically, HIF-PHIs should be used with caution in patients with a history of thrombosis or active malignancy. Patients without them may be preferable for HIF-PHIs if those are bothered with regular injections of ESAs or are hyporesponsive to ESAs without obvious reasons, provided that the drugs were approved in the country. Even so, clinicians must take caution for signs of adverse events such as heart failure after prescribing the drugs.
The method described serves for in vitro production of cartilage and of implants consisting at least partially of cartilage. It is based on living cells that are able to form an extracellular matrix of cartilage, and which are placed in an otherwise empty cell space (1), and are left in this cell space (1) to form an extracellular matrix of cartilage. As many cells are introduced into the cell space as necessary for it to contain about 5x10?7 to 109¿ cells per cubic centimetre. The cell space (1) is separated, at least partially, from a culture-medium space (2) surrounding the cell space (1) by a semipermeable wall (3), or by an open-pored wall that acts as a convection barrier. The open-pored wall may take the form of a plate (7) made of a bone-substitute material, and be located towards the bottom of the cell space (1). This causes the cells to be deposited on this plate (7), and the cartilage arising in the cell space (1) grows into its pores or surface irregularities, thus creating an implant consisting of a bone-substitute plate (7) and a layer of cartilage covering this, with the two parts of the implant having a positive form fit with one another resulting from the cartilage growing.
Effect sizes from previously reported trials are often used to determine the meaningful change in weight in childhood obesity prevention interventions because information on clinically meaningful differences is lacking. Estimates from previous trials may be influenced by statistical significance; therefore, it is important that they have a low risk of type 1 error. A systematic review and meta-analysis were conducted to report on the design of child obesity prevention randomized controlled trials and effectiveness according to risk of type 1 error. Eighty-four randomized controlled trials were identified. A large range of assumptions were applied in the sample size calculations. The most common primary outcome was BMI, with detectable effect size differences used in sample size calculations ranging from 0.25 kg/m2 (followed up at 2 years) to 1.1 kg/m2 (at 9 months) and BMI z-score ranging from 0.1 (at 4 years) to 0.67 (at 3 years). There was no consistent relationship between low risk of type 1 error and reports of higher or lower effectiveness. Further clarity of the size of a meaningful difference in weight in childhood obesity prevention trials is required to support evaluation design and decision-making for intervention and policy. Type 1 error risk does not appear to impact effect sizes in a consistent direction.
Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Bariatric surgery is the treatment of choice for morbid obesity, but it does not lead to equal results in every patients. Research about personality factors involved in successful outcome after bariatric surgery has led to contrasting results. The existing literature about potential predictors of success after bariatric surgery is far from conclusive. The investigators want to evaluate preoperatively by standardized diagnostic interviews (MINI, SCID-II) and rating scales and questionnaires to assess co-morbid psychopathology. The same evaluation will be done after 1,2 and 5 years. The investigators will look for a relationship between psychological variables and success after bariatric surgery, including amount of weight loss, psychiatric comorbidity, quality of life and employment. The investigators will also investigate the purpose of an pre- and postoperative psychological intervention. Patients on a waiting list for bariatric surgery are randomised to an intervention- and a control group. The intervention is based on cognitive behavior therapy and mindfulness, 6 weeks preoperative and two weeks postoperative programme. Outcome measures are amount of weight loss, psychiatric comorbidity, quality of life and employment.
Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
ADHD adolescents with a parent with bipolar disorder ("high-risk"). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
Baclofen injection (intrathecal), USP is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is:

Baclofen is a white to off-white, odorless or practically odorless crystalline powder, with a molecular weight of 213.66. It is slightly soluble in water, very slightly soluble in methanol, and insoluble in chloroform.

Baclofen injection (intrathecal), USP is a sterile, pyrogen-free, isotonic solution free of antioxidants, preservatives or other potentially neurotoxic additives indicated only for intrathecal administration. The drug is stable in solution at 37° C and compatible with CSF. Each milliliter of baclofen injection (intrathecal) contains baclofen U. S. P., 500 mcg or 2,000 mcg and sodium chloride 9 mg in Water for Injection; pH range is 5.0 to 7.0. Each vial is intended for SINGLE USE ONLY. Discard any unused portion. DO NOT AUTOCLAVE.
There is tremendous national enthusiasm for translating and disseminating efficacious strategies to prevent type 2 diabetes mellitus (T2DM). Yet, little attention has been devoted to how the investigators can better leverage the processes through which patients receive information about prevention of T2DM to better engage them in such prevention. Further, despite efforts to disseminate structured programs, many patients at high risk for developing T2DM may still be unable or unwilling to access them. In these cases, increasing patient engagement in individually directed lifestyle change or pharmacotherapy is critical. Strategies developed in the fields of behavioral economics and health psychology hold significant promise for improving Veteran engagement in each of these approaches. To date, however, these strategies have rarely been translated into real-world settings where they could benefit Veterans. This novel work will address this critical gap and could transform communication with Veterans about prevention in ways that will improve their health outcomes.

The following 5 strategies will be implemented in the weekly messages that study participants will receive: (1) tailoring to aspirations in life; (2) implementation intentions; (3) preference checklists; (4) urgency framing; (5) social norms. The investigators will implement these strategies alone and in combination in a 16-arm factorial design experiment.
Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.